At ACA Pharma, we specialize in fast-track registration and tailored market entry solutions for Asia. Our services include streamlined registration in Macau, Hong Kong, and Singapore for new and innovative drugs, enabling rapid access to the Asian market. Through initiatives like the Asian Patient Access Program (APAP), we provide flexible solutions to meet urgent patient needs and empower originators to swiftly expand sales to unregistered regions worldwide, leveraging our extensive physician network.

• 54 New Drugs Registered; 7 in Submission Process
• Quick Registration in Macau (30-90 Days)
• 100% Registration Success Rate
• No Additional Clinical Trials Required
• Zero Additional Investment Needed

Critical Care Solutions

• Pediatric and Clinically Urgent Medications: Upon successful registration in Macau, these drugs can quickly access major hospitals in Beijing, Shanghai, Tianjin, Hainan, and Chongqing, as well as the top ten pediatric hospitals nationwide, which treat over 50% of China’s rare disease patients. Classified as clinically urgent and irreplaceable, these medications benefit from a streamlined approval process, entering leading hospitals without the need for national registration or clinical trials.
• Fast-Track National Approval: Leveraging initial real-world data collected after Macau registration, national registration is typically completed within 3-6 months for Pediatric Orphan Drugs and 6-12 months for Clinically Urgent Medicines. This streamlined process ensures timely access to critical treatments for patients in need.
• Media Coverage for Broader Awareness: Extensive media coverage ensures patients across the country who can afford out-of-pocket treatments are informed and can receive timely medical assistance.

Accelerate access to treatment with Fast Track Registration in Macau for drugs addressing unmet medical needs. Our streamlined process allows originators of innovative and clinically urgent drugs to swiftly enter the Chinese market, facilitating rapid recovery of their development investments.